Sugi Predict

Sugi Predict / Compounds / SCHEMBL1194569

SCHEMBL1194569

SCHEMBL1194569

O=S(=O)(/C=C/c1ccccc1)/C=C/c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 7/20 0.57
▸ LMNA P02545 4/20 0.57
▸ NFE2L2 Q16236 2/20 0.57
▸ MAOB P27338 1/20 0.50
▸ PKM P14618 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ TRPA1 O75762 1/20 0.48
▸ ALOX5 P09917 1/20 0.48
▸ HSP90AA1 P07900 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ TNKS O95271 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HCAR2 Q8TDS4 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL587895 1.00 PPARG (0.57) PPARGLMNANFE2L2MAOBPKM
SCHEMBL19155588 1.00 PPARG (0.57) PPARGLMNANFE2L2MAOBPKM
SCHEMBL3730162 1.00 PPARG (0.57) PPARGLMNANFE2L2MAOBPKM
SCHEMBL15845143 0.97 PPARG (0.55) PPARGLMNANFE2L2MAOBPKM
SCHEMBL21647828 0.97 PPARG (0.55) PPARGLMNANFE2L2MAOBPKM
SCHEMBL10622974 0.86 PPARG (0.50) PPARGLMNANFE2L2MAOBPKM
SCHEMBL1120113 0.84 PPARG (0.44) PPARGLMNANFE2L2PKMKMT2A
SCHEMBL1120116 0.84 PPARG (0.44) PPARGLMNANFE2L2PKMKMT2A
SCHEMBL6207937 0.82 PPARG (0.55) PPARGLMNANFE2L2MAOBPKM
SCHEMBL6207941 0.82 PPARG (0.55) PPARGLMNANFE2L2MAOBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3702347-B1 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE AMGEN EUROPE GMBH (CH) 2023-11-08 — — EP claimed
EP-3702347-A1 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE Amgen (Europe) GmbH (CH) 2020-09-02 — — EP claimed
EP-2817288-B1 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE CELGENE CORP (US) 2018-05-30 — — EP claimed
CN-107033042-A For the technique for preparing (S) 1 (methoxyphenyl of 3 ethyoxyl 4) 2 methane sulfonyl ethamine 细胞基因公司 2017-08-11 — — CN claimed
US-9187417-B2 Processes for the preparation of (S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine CELGENE CORPORATION (US) 2015-11-17 — — US claimed
EP-2817288-A2 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE Celgene Corporation (US) 2014-12-31 — — EP claimed
CN-104245668-A Process for the preparation of -1- (3-ethoxy-4-methoxyphenyl) -2-methanesulfonylethylamine CELGENE CORP 2014-12-24 — — CN claimed
WO-2013126360-A2 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE CELGENE CORPORATION (US) 2013-08-29 — — WO claimed
US-20130217918-A1 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE CELGENE CORPORATION (US) 2013-08-22 — — US claimed
EP-0596485-B1 Electrochemical process for preparing alcoholates of alkaline metal and use thereof for regenaration of the catalyst in the synthesis of methylformat SALZGITTER ANLAGENBAU (DE) 1996-01-03 — — EP claimed
JP-4140727-A — — None — — JP disclosed
EP-4739306-A2 POLO-LIKE KINASE 1 INHIBITORS Cervero Therapeutics, LLC (US) 2026-05-13 — — EP disclosed
US-12410124-B2 Carbamate-substituted styryl sulfone compounds, preparation method and use thereof HUAXIASHENGSHENG PHARMACEUTICAL BEIJING CO., LTD. (CN) 2025-09-09 — — US disclosed
EP-4583982-A1 CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS Cardiff Oncology, Inc. (US) 2025-07-16 — — EP disclosed
CN-112384505-B Therapeutic heterocyclic compounds 吉利德科学公司 2025-05-27 — — CN disclosed
EP-1027330-A1 STYRYL SULFONE ANTICANCER AGENTS Temple University of the Commonwealth System of Higher Education (US) 2000-08-16 — — EP disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 — — WO disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 — — WO disclosed
WO-1999018068-A1 STYRYL SULFONE ANTICANCER AGENTS TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 1999-04-15 — — WO disclosed
JP-H04140727-A NONLINEAR OPTICAL MATERIAL NIPPON OIL & FATS CO LTD 1992-05-14 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410124-B2 Carbamate-substituted styryl sulfone compounds, preparation method and use thereof ACHE, BCHE, CHAT PPARG 648/4885LMNA 3533/4885NFE2L2 2183/4885
US-20130217918-A1 PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE TNF, SMS, SRM PPARG 4244/4885LMNA 1745/4885NFE2L2 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.